Precision Medicine

The IHR conducts research aimed at improving precision medicine approaches in care delivery to inform guidelines for best practices both locally at Kaiser Permanente Colorado and nationally. The use of precision medicine technologies to identify targeted treatment or care plans based on an individual patient's risk factors, genes, and disease characteristics is a critical area of medical research nationwide. IHR researchers are working to find novel approaches in precision medicine by evaluating biomarkers in cancer precursor lesions, improving data capture and tracking for tests related to precision medicine, and understanding how members and clinicians understand and use precision medicine information.


Recent Publications

Precision Medicine Researchers

  • Andrea Burnett-Hartman, PhD, MPH
    Investigator

Featured Projects

  • +

    Serrated Colorectal Cancer: An Emerging Disease Subtype

    Investigators: Andrea Burnett-Hartman, PhD, MPH
    The objective of this project is to characterize factors relating to the genetic predisposition, clinical presentation, and prognosis of serrated colorectal cancer.
    Funder:National Cancer Institute
    Study End Date: 4/30/2021
  • +

    Kaiser Permanente National Research Bank

    Investigators: Andrea Burnett-Hartman, PhD, MPH and Heather Spencer Feigelson, PhD, MPH
    The KP National Biobank is a collaboration across all Kaiser regions funded by the Kaiser Foundation Health Plan. The goal of the biobank is to collect blood and/or tissue samples on 400,000 Kaiser Permanente members and utilize them, combined with survey data and medical information, to create a state-of-the-art resource for genetic and health services research.
    Funder:Kaiser Foundation Health Plan
    Study End Date: 12/31/2019
  • +

    Clinical Sequencing Evidence-Generating Research (CSER2)

    Investigators: Heather Spencer Feigelson, PhD, MPH
    The goal of this project is to investigate the implementation of exome sequencing in practice settings that primarily serve racially, ethnically, and socioeconomically diverse patients while examining the needs of both patients and clinicians. We will evaluate the clinical utility of exome sequencing in healthy adults of reproductive age at risk for hereditary cancer syndromes (Lynch Syndrome and Hereditary Breast and Ovarian Cancer). We will evaluate and tailor for diverse populations the critical interactions in the program, including the consent process, choices for reporting additional findings, and the response to results disclosure.
    Funder:National Human Genome Research Institute
    Study End Date: 5/31/2021